Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.
Kageaki WatanabeKiyotaka YohYukio HosomiKazuhiro UsuiGo NakaKazuma KishiKohei UemuraYasuo OhashiHideo KunitohPublished in: BMJ open (2022)
UMIN000038683.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- study protocol
- tyrosine kinase
- randomized controlled trial
- clinical trial
- healthcare
- palliative care
- signaling pathway
- quality improvement
- small cell lung cancer
- double blind
- open label
- cross sectional
- chronic pain
- combination therapy
- replacement therapy
- smoking cessation